Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis

Abstract Background Erythropoiesis‐stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MD...

Full description

Bibliographic Details
Main Authors: Enrico Balleari, Rosa Angela Filiberti, Chiara Salvetti, Bernardino Allione, Emanuele Angelucci, Marco Bruzzone, Tullio Calzamiglia, Marina Cavaliere, Maurizio Cavalleri, Daniela Cilloni, Marino Clavio, Elena Crisà, Anna Da Col, Paolo Danise, Federica Pilo, Dario Ferrero, Carlo Finelli, Daniela Gioia, Roberto Massimo Lemoli, Elisa Masiera, Emanuela Messa, Maurizio Miglino, Pellegrino Musto, Esther Natalie Oliva, Antonella Poloni, Flavia Salvi, Alessandro Sanna, Marco Scudeletti, Rodolfo Tassara, Valeria Santini
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Cancer Medicine
Subjects:
anemia
erythropoietin
myelodysplastic syndromes
Online Access:https://doi.org/10.1002/cam4.2638

Internet

https://doi.org/10.1002/cam4.2638

Similar Items